Impact of Alemtuzumab on Health-Related Quality of Life Over 6 Years in CARE-MS II Trial Extension Patients With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis - United States
doi 10.1177/1352458519849796
Full Text
Abstract

Available in full text

Categories
Neurology
Date
Authors
Publisher

SAGE Publications

Related search

Acute Effects of Alemtuzumab Infusion in Patients With Active Relapsing-Remitting MS

Neurology: Neuroimmunology and NeuroInflammation
Neurology
2016English

Change in the Health-Related Quality of Life of Multiple Sclerosis Patients Over 5 Years

International Journal of MS Care
NeurologySpecialized NursingAdvanced
2013English

Alemtuzumab: Evidence for Its Potential in Relapsing–remitting Multiple Sclerosis

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2013English

The Impact of Pain and Other Symptoms on Quality of Life in Women With Relapsing-Remitting Multiple Sclerosis

Journal of Neuroscience Nursing
EndocrineMedicalAutonomic SystemsSurgical NursingNeurologySurgery
2009English

Long-Term Safety and Efficacy of Natalizumab in Relapsing-Remitting Multiple Sclerosis: Impact on Quality of Life

Patient Related Outcome Measures
2014English

Cognitive Profile of Patients With Relapsing Remitting Multiple Sclerosis

Arquivos de Neuro-Psiquiatria
Biological PsychiatryNeurology
1999English

Health State Utilities in Patients With Relapsing Remitting Multiple Sclerosis Treated With Cladribine Tablets

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Alemtuzumab: A Review of Efficacy and Risks in the Treatment of Relapsing Remitting Multiple Sclerosis

Therapeutics and Clinical Risk Management
2017English

Comparing the Quality of Life Among Patients With Relapsing Remitting Multiple Sclerosis in Iraq Using Different Disease Modifying Therapies

Iraqi Journal of Pharmaceutical Sciences
ToxicologyAnalytical ChemistryPharmaceuticsPharmacology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy